WHO wants public-health AI evidence for India—but the published annex still has gaps
A two-year WHO–LEHS agreement promises public evidence on safety, effectiveness, cost and adoption. The attached concept note still contains draft wording, placeholders and unreconciled claims, so it is a plan for evaluation—not proof that an AI tool works.
The short version
- What happened
- WHO South-East Asia and the Lords Education and Health Society, through Wadhwani AI, published a two-year collaboration running from 1 November 2026 to 31 October 2028.
- Who it affects
- Frontline workers and public-health managers could eventually receive AI-supported screening, documentation or population tools. Their decisions should depend on published validation, workload, error, equity and cost evidence—not on programme reach claims that remain unresolved in a draft annex.
- What remains unproven
- Official announcement
Keep in mind
Official announcement
Two-year collaboration
No named AI product
No study sample
No comparator
No measured patient outcome
No funding transfer envisaged
Draft language in annex
Unreconciled reach figure
LEHS claims not independently verified by WHO
Source analysis · 2 linked sources. Primary analysed source date: 30 October 2026.
Keep following the evidence
Join The Impact Brief founding list for selected AI reports, their effect on people and the evidence limits. Read a sample first.
Read the full report · 4 min The evidence, methods, implications and limitations
The commitment is to produce evidence, not to endorse a product
WHO's South-East Asia office and the Lords Education and Health Society have published a two-year collaboration intended to examine AI in India's public-health system. Starting 1 November, the parties plan technical briefs, case studies and evaluation reports on operational feasibility, safety, effectiveness, cost-effectiveness and user adoption. India and state governments retain decisions about selection, procurement and deployment; the agreement says WHO will not certify or endorse a Wadhwani AI product.
For frontline health workers and programme managers, that could eventually make implementation evidence easier to inspect across diagnostics, risk stratification and disease tracking. But the announcement names no specific model, public-health programme, study sample, comparator or measured result. Each party bears its own costs at this stage, and future activities remain subject to available resources and government decisions.[1][2]
The public annex needs clarification before its claims can be used
The attached 12-page file contains a formal agreement and an annexed concept note, but the annex still says “Draft for discussion” and “creates no commitment”. It also retains editing prompts about LEHS's legal status and WHO programme alignment. Most importantly, it presents an unverified claim that Wadhwani AI-supported services reached “[150 / 200] million” people and were associated with a 30% reduction in combined loss to follow-up and mortality, followed by instructions to reconcile the figures and cite evidence. Those numbers are not a usable denominator or outcome and are not repeated in WHO's public announcement.
What would change the assessment is straightforward: a final clean work plan, named interventions, preregistered methods, patient and workflow denominators, credible comparators, subgroup results, costs, errors and independently reviewed public reports. Until then, the consequential development is a commitment to generate evidence across a large public-health setting—not evidence that the deployed AI is safe, effective or equitable.[2]
The distinction that matters
What is agreed, promised and still missing
The source trail separates a two-year institutional agreement from future evaluation work and from claims that remain unresolved in the annex.
Agreed
Two-year WHO–LEHS collaboration from 1 November 2026
A framework for evidence and capacity work, with each party bearing its own costs
Promised
Technical briefs, case studies and evaluation reports
Safety, effectiveness, cost and adoption should become publicly inspectable
Missing
No named evaluation, denominator or result yet
Draft placeholders and unreconciled claims cannot establish impact
Watch the background, then check the evidence
Illustrative photo · not a video frame
The Royal Society · 44 min 28 sec · Background explainer
Is this the AI future we want? | The Royal Society
YouTube loads only when you choose; playback starts when you press play.
A Royal Society discussion with Madhumita Murgia and biomedical engineer Alison Noble on AI’s potential in healthcare, science and culture, recorded at the 30 June 2026 event.
Evidence check: A discussion of opportunities and risks, including future possibilities. It is not evidence that every application described is available or clinically proven.
Published 2026-07-01. Source checked 14 October 2026. Check captions on the publisher’s video page.
Check the healthcare evidencePhoto: Daniel Sone / National Cancer Institute / Unsplash · Licence
Continue the story
Read next
Continue exploring public health: compare the finding and its evidence limits.
Where is AI actually being used in public health? A review found only eight reports
Researchers screened 5,400 records and 155 full texts but found only eight reports describing AI used in public-health practice relevant to high-income countries outside outbreaks. The evidence was mixed and usually did not test effectiveness.
Read the next reportExplore the full source and evidence record
What this means for people
- Frontline workers and public-health managers could eventually receive AI-supported screening, documentation or population tools. Their decisions should depend on published validation, workload, error, equity and cost evidence—not on programme reach claims that remain unresolved in a draft annex.
Global context
The collaboration is centred on India but is intended to inform other WHO South-East Asia Member States. Health systems, connectivity, workforce roles, disease burdens, privacy law and procurement differ across the region; lessons cannot be assumed to transfer without local evaluation.
What the evidence does not yet show
- Official announcement
- Two-year collaboration
- No named AI product
- No study sample
- No comparator
- No measured patient outcome
- No funding transfer envisaged
- Draft language in annex
- Unreconciled reach figure
- LEHS claims not independently verified by WHO
What to watch next
- A clean final work plan
- Named programmes and models
- Preregistered evaluation protocols
- Patient and workflow denominators
- Independent review
- Public safety and effectiveness results
- Cost-effectiveness
- User adoption and workload
- Equity and subgroup outcomes
- Clarification of the draft annex
Living evidence record
Impact record IAI-03RWES8
Evidence stage
Announced
Confidence
Supported
Reporting basis
Source analysis
Independent or research support
Not yet
Record status
Monitoring
Last checked
30 October 2026
Source trail
2 direct sources across 2 source types.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Related-source reporting disclosure
This record analyses 2 linked source records around the same underlying development. The extra records add method, date or context, but they do not by themselves constitute independent replication of every performance claim or predicted outcome.
Evidence trail
Sources used for this report
Links checked 30 October 2026
Research question, topics and regions
What the WHO–LEHS public-health AI collaboration commits to evaluate, and what its published documents do not yet establish
Topics: Public health · Health AI · Evidence generation · Government systems · Equity · Implementation
Regions: India · Asia · South-East Asia
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Reader commentary
What does this mean where you are?
Tell us what you have seen at work, in your community or in everyday life. A question is welcome too. No account is needed; we review notes before publishing them.
Explore commentary across the portal →Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.